Sensei Biotherapeutics 대차 대조표 상태

재무 상태 기준 확인 6/6

Sensei Biotherapeutics 의 총 주주 지분은 $45.8M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $53.3M 및 $7.5M 입니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	n/a
현금	US$47.00m
주식	US$45.78m
총 부채	US$7.48m
총 자산	US$53.25m

최근 재무 상태 업데이트

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Jul 02

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Mar 14

Recent updates

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Nov 03

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Jul 02

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Mar 14

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Aug 14

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Aug 09

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Apr 18

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Nov 16

재무 상태 분석

단기부채: SNSE 의 단기 자산 ( $48.1M )이 단기 부채( $5.4M ).

장기 부채: SNSE 의 단기 자산( $48.1M )이 장기 부채( $2.0M ).

부채 대 자본 내역 및 분석

부채 수준: SNSE 부채가 없습니다.

부채 감소: SNSE 현재 부채가 없지만 해당 기간에 대한 데이터가 없기 때문에 5년 전과 비교할 수 없습니다.

대차 대조표

현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: SNSE 현재 무료 현금 흐름을 기준으로 1년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: SNSE 13.9 1.6 13.9 % 매년.

Sensei Biotherapeutics 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Sensei Biotherapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(a)(1)

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Sensei Biotherapeutics Receives Non-Compliance Notice from Nasdaq

Sensei Biotherapeutics Receives Non-Compliance Notice from Nasdaq

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Recent updates

Sensei Biotherapeutics, Inc. to Close its Research Site in Rockville, Maryland and Reduce its Workforce by Approximately 46%

Sensei Biotherapeutics Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(a)(1)

Price target decreased by 13% to US$4.33

Sensei Biotherapeutics, Inc., Annual General Meeting, Jun 11, 2024

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

New minor risk - Share price stability

Sensei Biotherapeutics, Inc. Announces Management Changes

High number of new directors

Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc. (NasdaqGM:SNSE).

Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer

Sensei Biotherapeutics, Inc. to Present Initial Clinical Data from Dose Escalation Trial of SNS 101 At 2023 SITC Annual Meeting

Sensei Biotherapeutics Receives Non-Compliance Notice from Nasdaq

Sensei Biotherapeutics Receives Non-Compliance Notice from Nasdaq

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo

Sensei Biotherapeutics, Inc. Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

Sensei Biotherapeutics, Inc., Annual General Meeting, Jul 10, 2023

Sensei Biotherapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101

Sensei Biotherapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

High number of new directors

eSensei Biotherapeutics, Inc. Announces Reduction of Total Workforce

Sensei Biotherapeutics, Inc. Announces Executive Changes

High number of new and inexperienced directors

Sensei Biotherapeutics, Inc. Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Apeiron Investment Sends a Letter to Sensei Biotherapeutics

Sensei Biotherapeutics, Inc. Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Sensei Biotherapeutics, Inc. Announces New Preclinical Data Demonstrating Favorable Pharmacokinetic and Immunologic Effects of SNS-101, A Ph-Selective Vista-Blocking Antibody

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Sensei Biotherapeutics, Inc.(NasdaqGM:SNSE) dropped from Russell 2500 Value Index

Sensei Biotherapeutics Appoints Patrick Gallagher, MBA, MPH, as Chief Business Officer

Price target decreased to US$8.00

High number of new and inexperienced directors

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Price target decreased to US$11.00

Chairman of The Board recently bought US$80k worth of stock

Chairman of The Board recently bought US$136k worth of stock

Chairman of The Board recently bought US$53k worth of stock

Independent Director recently bought US$57k worth of stock

Independent Director recently bought US$250k worth of stock

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Chief Scientific Officer recently sold US$568k worth of stock

Sensei Biotherapeutics, Inc.(NasdaqGM:SNSE) dropped from Russell 3000E Growth Index

Sensei Biotherapeutics, Inc. Announces New Clinical Data from the Ongoing Phase 1/2 Combination Trial of SNS-301 in Patients with Squamous Cell Carcinoma of the Head and Neck

Sensei Biotherapeutics, Inc. announced that it has received $34.5 million in funding from a group of investors

Independent Director recently bought US$143k worth of stock

Independent Director recently bought US$233k worth of stock

Sensei Biotherapeutics Appoints Deneen Vojta to the Board of Directors

Sensei Biotherapeutics, Inc. has completed an IPO in the amount of $133.000988 million.

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

현금 런웨이 분석

건강한 기업 발견하기